Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients
Stopped At the end of the planned recruitment period the expected number of subjects could not be included in the trial.
Conditions
Interventions
- DRUG: pegylated interferon alpha-2b
- DRUG: Ribavirin
- DRUG: pegylated Interferon alpha-2b
- DRUG: Ribavirin
Sponsor
HepNet Study House, German Liverfoundation
Collaborators